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Abstract
Arginine vasopressin (AVP) is synthesized in parvocellular- and magnocellular neuro-
endocrine neurons in the paraventricular nucleus (PVN) of the hypothalamus.
Whereas magnocellular AVP neurons project primarily to the posterior pituitary,
parvocellular AVP neurons project to the median eminence (ME) and to
extrahypothalamic areas. The AVP gene encodes pre-pro-AVP that comprises the sig-
nal peptide, AVP, neurophysin (NPII), and a copeptin glycopeptide. In the present
study, we used an N-terminal copeptin antiserum to examine copeptin expression in
magnocellular and parvocellular neurons in the hypothalamus in the mouse, rat, and
macaque monkey. Although magnocellular NPII-expressing neurons exhibited strong
N-terminal copeptin immunoreactivity in all three species, a great majority (90%) of
parvocellular neurons that expressed NPII was devoid of copeptin immunoreactivity
in the mouse, and in approximately half (53%) of them in the rat, whereas in mon-
key hypothalamus, virtually all NPII-immunoreactive parvocellular neurons contained
strong copeptin immunoreactivity. Immunoelectron microscopy in the mouse clearly
showed copeptin-immunoreactivity co-localized with NPII-immunoreactivity in
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neurosecretory vesicles in the internal layer of the ME and posterior pituitary, but
not in the external layer of the ME. Intracerebroventricular administration of a
prohormone convertase inhibitor, hexa-D-arginine amide resulted in a marked reduc-
tion of copeptin-immunoreactivity in the NPII-immunoreactive magnocellular PVN
neurons in the mouse, suggesting that low protease activity and incomplete
processing of pro-AVP could explain the disproportionally low levels of N-terminal
copeptin expression in rodent AVP (NPII)-expressing parvocellular neurons. Physio-
logic and phylogenetic aspects of copeptin expression among neuroendocrine neu-
rons require further exploration.
K E YWORD S
copeptin, hypothalamo-pituitary–adrenal system, immunohistochemistry, paraventricular
nucleus of the hypothalamus, processing, vasopressin, RRID: AB_2722604, RRID: AB_2061966,
RRID: AB_2314234, RRID: AB_10013361, RRID: AB_2313960, RRID: AB_2722605, RRID:
AB_90782
1 | INTRODUCTION
Arginine vasopressin (AVP) is a neuropeptide produced in various
hypothalamic nuclei. The magnocellular neurons in the paraventricular
nucleus (PVN) and the supraoptic nucleus (SON) of the hypothalamus,
and small-sized neurons located in the dorsomedial portion of the
suprachiasmatic nucleus (SCN), are stained intensely with antibodies
against AVP or neurophysin (NP) II (Ben-Barak, Russell, Whitnall,
Ozato, & Gainer, 1985; Castel & Morris, 1988; Otero-Garcia
et al., 2014). Axons of AVP-producing neurons, originating from the
magnocellular neurons in the PVN and the SON, traverse the internal
layer of the median eminence (ME) and project to the posterior pitui-
tary, where AVP is released into the systemic circulation from the
axon terminals (Burbach, Luckman, Murphy, & Gainer, 2001). Produc-
tion of AVP in the PVN and the SON, as well as its release from the
posterior pituitary, is regulated by osmotic pressure and/or body fluid
volume (Koshimizu et al., 2012; Murphy, Waller, Fairhall, Carter, &
Robinson, 1998). AVP is also released from the dendrites of mag-
nocellular neurons into hypothalamic neuropil, and is involved in the
autocrine regulation of magnocellular neurons and paracrine regula-
tion of other neurons in a variety of functions (Johnson &
Young, 2017; Ludwig & Leng, 2006). Although SCN neurons are not
part of neuroendocrine systems, AVP is also produced in the dors-
omedial (shell) part of the SCN (Golombek & Rosenstein, 2010;
Ramkisoensing & Meijer, 2015). Physiological roles of AVP in the SCN
are still obscure, but it has been hypothesized to be involved in
diverse mechanisms in the brain, which are related to the control of
circadian rhythm (Gizowski, Zaelzer, & Bourque, 2016; Trudel &
Bourque, 2010).
In the PVN, corticotropin-releasing factor (CRF)-producing neu-
rons, located mainly in the anteromedial part of the nucleus, comprise
a third population of neuroendocrine neurons that is capable of pro-
ducing AVP (Fellmann et al., 1984; Itoi et al., 2014;Mouri et al., 1993;
Whitnall, 1993). These neurons are parvocellular neurons which
project to the external layer of the ME, where CRF and AVP are
released into the pituitary portal vessels from nerve endings terminat-
ing on the capillary bed (Fellmann et al., 1984). Both CRF and AVP
stimulate adrenocorticotropin (ACTH) secretion from corticotrophs in
the anterior pituitary, and they act synergistically in ACTH secretion
when applied together to anterior pituitary cells (Fischman &
Moldow, 1984; Gillies, Linton, & Lowry, 1982; Hashimoto, Murakami,
Hattori, & Ota, 1984; Liu et al., 1983; Murakami, Hashimoto, &
Ota, 1984; Rivier & Vale, 1983; Vale et al., 1983). The concentration
of AVP in the pituitary portal vessels increases when animals are
stressed (Plotsky, 1987) or have undergone adrenalectomy (Plotsky &
Sawchenko, 1987). In rats, CRF and AVP are co-packaged into the
same neurosecretory vesicles in the CRF- and AVP-double positive (+)
subpopulation of axons in the ME, where they can be co-released
from the nerve endings of the parvocellular neurons (Whitnall,
Mezey, & Gainer, 1985). Therefore, both CRF and AVP are regarded
as physiological secretagogues for ACTH in the pituitary (Mouri
et al., 1993; Whitnall, 1993).
A fourth population of AVP-producing neurons in the PVN is
located in the posterolateral part of the nucleus. These cells are cate-
gorized as parvocellular neurons, and they project to
extrahypothalamic areas and to the spinal cord, and are thought to be
involved in the regulation of autonomic output (Sawchenko, 1987).
The AVP gene encodes pre-pro-AVP, which is a precursor protein
comprising the signal peptide, AVP, NPII, and a 39-aminoacid glyco-
peptide often called copeptin (Breslow, 1993; Davies, Waller, Zeng,
Wells, & Murphy, 2003; Land, Schutz, Schmale, & Richter, 1982).
After removal of the signal-peptide in the endoplasmic reticulum, the
precursor protein is packaged into neurosecretory vesicles in the
Golgi apparatus (Burbach et al., 2001; Davies et al., 2003). It is then
subjected to post-translational cleavage by enzymes (prohormone
convertases) and co-packaged in vesicles during its axonal transport
to terminals (Hook et al., 2008). In the magnocellular neurons which
project to the posterior pituitary, PC1/3, PC2, furin, and PC7 were all
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strongly expressed. In the parvocellular CRF neurons, however, there
was little or no expression of PC1 although PC2, furin, and PC7 were
expressed there (Dong et al., 1997). At this moment, we have no
knowledge of proteases in parvocellular AVP neurons that project to
other regions of the brain. It is not yet clear what enzyme(s) cleaves
copeptin from the NP moiety of the pre-pro-AVP, either. Copeptin
constitutes the C-terminal part of the AVP precursor, and in mag-
nocellular neurons, its cleavage from the precursor is completed at
the level of posterior pituitary (Morgenthaler, Struck, Jochberger, &
Dunser, 2008). Copeptin is also glycosylated, which is important for
the stability of the peptide in the circulation (Bhandari et al., 2009;
Blanchard et al., 2013; Bolignano et al., 2014; Wuttke et al., 2013).
Activation of the AVP neurons projecting to the neurohypophysis stim-
ulates secretion of both AVP and copeptin into systemic circulation on
an equimolar basis (Morgenthaler et al., 2008). Activation of CRF/AVP
neurons projecting to the ME are primarily stimulated by stress, and
particular chronic stress, leading to increases in AVP expression in
these neurons (de Goeij, Jezova, & Tilders, 1992; Sawchenko, Arias, &
Mortrud, 1993). However, it has not been elucidated whether AVP and
copeptin are released simultaneously into the portal capillaries.
Copeptin is produced as a co-product of AVP and NPII, as
described above, and the AVP gene is expressed in all populations of
AVP-producing neurons in the hypothalamus, i.e., the magnocellular
neurons in the PVN and the SON, the parvocellular CRF neurons in
the PVN, the dorsomedial group of SCN neurons, and the pre-
autonomic neurons in the posterolateral part of the PVN. In the
present immunofluorescence study, we used either an N-terminal
copeptin antiserum or a C-terminal antiserum, together with an NPII
antiserum, to examine the presence of copeptin in the hypothalamus
of mice, rats, and macaque monkeys by immunofluorescence, and elu-
cidated the co-localization of copeptin with AVP/NPII in somata of
hypothalamic neuroendocrine neurons, as well as in their nerve end-
ings in the ME. Furthermore, an immunoelectron microscopic analysis
was carried out in the mouse to examine the subcellular localization of
copeptin. Special attention was paid to the co-localization of copeptin
with AVP/NPII within secretory vesicles. Remarkably, copeptin immu-
noreactivity was not uniform in different populations of AVP-produc-
ing neurons. In addition, there was a marked species difference in
copeptin-immunoreactivity in the parvocellular neurosecretory neu-
rons in the PVN.
2 | MATERIALS AND METHODS
2.1 | Animals
Adult male and female mice of the C57BL6 strain (10–12-week-old)
were used in this study. For experiments probing the CRF-expressing
neurons, adult male CRF-VenusΔNeo mice (C57BL6 strain) (Kono
et al., 2017) bred in the animal facilities of Tohoku University were
used. Adult male rats of the Wistar strain (10–12-week-old) were also
used. Mice and rats were maintained according to the established pro-
cedure as described elsewhere (Kono et al., 2017; Sakamoto et al.,
2008). Male and female Japanese macaque monkeys, Macaca fuscata
(n = 2; 2–3-year-old males, weight 2.4–2.9 kg; n = 2; 10–11-year-old
females, weight 7.2–8.1 kg) were also used in this study. Animals were
maintained in a temperature-controlled (22–24C) room under a daily
photoperiod of 12/12-hr light/dark cycle (lights on 8:00 a.m.–8:00 p.m.).
These animals were shown to be free of specific pathogens. Food and
water were available ad libitum. The housing and experimental proto-
cols followed the guideline of the Ministry of Education, Culture,
Sports, Science, and Technology (MEXT) of Japan, and were in accor-
dance with the Guide for the Care and Use of Laboratory Animals
prepared by Okayama University (Okayama, Japan), by Tohoku Uni-
versity (Miyagi, Japan), by Kyoto Prefectural University of Medicine
(Kyoto, Japan), and by Kansai Medical University (Osaka, Japan). All
efforts were made to minimize animal suffering and reduce the num-
ber of animals used in this study.
2.2 | Tissue preparation
Mice, rats, and monkeys were anesthetized with an overdose of
sodium pentobarbital (50–90 mg/kg body weight), and transcardially
perfused with physiological saline followed by 4% paraformaldehyde
(PFA) (for immunohistochemistry and immunofluorescence; 17 male
and four female mice; four CRF-VenusΔNeo adult male mice; four male
rats; two male and two female Japanese macaque monkeys) or by 4%
PFA + 0.1% glutaraldehyde (for electron microscopic studies; five
male mice), both in 0.1 M phosphate buffer (PB, pH 7.4). Brains and
neurohypophyses were immediately removed and immersed in 4%
PFA in 0.1 M PB for 16–24 hr (for immunohistochemistry and immu-
nofluorescence) at 4C, or in 4% PFA + 0.1% glutaraldehyde in 0.1 M
PB for 3 hr at room temperature (for electron microscopy). Tissues for
immunofluorescence were then cryoprotected by immersion in 25%
sucrose in 0.1 M PB at 4C until they sank, then quickly frozen using
powdered dry ice and cut into 30-μm-thick coronal sections on a cryo-
stat (CM3050 S; Leica, Nussloch, Germany). For electron microscopy,
the fixed mouse brains were sectioned in the frontal plane at 200 μm
thickness with a Linear-Slicer (PRO10; Dosaka EM, Kyoto, Japan) and
were immersed in 0.1 M PB.
2.3 | Immunohistochemistry and
immunofluorescence
For immunohistochemistry, endogenous peroxidase activity was
quenched by incubation with 1% H2O2 in absolute methanol for
20 min and the sections were then rinsed with PBS three times for
5 min each. These processes were omitted for immunofluorescence.
After blocking nonspecific binding with 1% normal goat serum
(or normal donkey serum for the goat primary antiserum) and 1% BSA
in PBS containing 0.3% Triton X-100 for 30 min at room temperature,
the sections were incubated with primary rabbit antiserum raised
against an 8-amino acid N-terminal sequence (ATQLDGPA) of
copeptin (CP8, 1:20,000 dilution) (Satoh et al., 2015) (RRID:
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AB_2722604) or raised against C-terminus fragment of mouse
copeptin (m-20, 1:30,000 dilution) (Santa Cruz Biotechnology, Dallas,
TX) (RRID: AB_2061966) overnight at 4C. Immunoreactivity was
detected with a streptavidin-biotin kit (Nichirei, Tokyo, Japan),
followed by DAB development according to our previously reported
method (Sakamoto et al., 2008).
To demonstrate co-expression of copeptin or CRF in AVP neu-
rons, double-immunofluorescence staining for copeptin (1:10,000
dilution), AVP (1:2,000 dilution), or CRF (1: 20,000 dilution) and
AVP-NPII (1:1,000 dilution), or oxytocin-NPI (1:1,000 dilution) was
performed. A rabbit polyclonal antiserum for AVP (Chemicon,
Temecula, CA) (RRID: AB_90782) was used. Mouse monoclonal
antibodies for NPII (PS41; RRID: AB_2313960) and NPI (PS60;
RRID: AB_2722605) were used, and have previously been shown
to be specific for AVP and oxytocin neurons, respectively (Castel,
Morris, Whitnall, & Sivan, 1986; Wang, Ward, & Morris, 1995). The
rabbit polyclonal antiserum against rat CRF (PBL rC70; RRID:
AB_2314234), which was kindly donated by Wylie Vale, has been
characterized elsewhere (Sawchenko, Swanson, & Vale, 1984).
Specific staining for AVP and CRF were abolished by pre-
adsorption of the antisera for 1 hr at room temperature with
50 μg/ml synthetic AVP or mouse CRF before use. We further con-
firmed by Western blot analysis the specificity for the NPII anti-
body. The monoclonal antibody (PS41) labeled a single band at
approximately the expected molecular weight of 11 kDa on the
blots of mouse, rat, and macaque monkey posterior pituitary.
Western blot analysis also showed the specificity for the NPI anti-
body (PS60) in the mouse posterior pituitary. A goat polyclonal
antiserum for copeptin (m-20) raised against an oligopeptide near
the C-terminus of copeptin of mouse origin at a dilution of
1:15,000 was also used as described previously (Itoi et al., 2014).
Control procedures for the DAB method were performed using
pre-absorption of the working dilution (CP-8; 1:20,000 or m-20;
1:30,000) of the primary antiserum with a saturating concentration
of the antigen (50 μg/ml; N-terminus fragment of mouse
copeptin7–14 [ATQLDGPA] or C-terminus fragment of mouse
copeptin20–39 [RLVQLAGTRESVDSAKPRVY]) for 1 hr at room tem-
perature before use. Immunostained sections were observed under
the Olympus FSX100 microscope (Tokyo, Japan).
To detect the Venus signals in tissues from CRF-VenusΔNeo mice,
we performed immunofluorescence for detection of green fluorescent
protein (GFP) to intensify the Venus signal (for localizing CRF neurons)
as described previously (Kono et al., 2017). Primary rat monoclonal
anti-GFP antibody (1:10,000 dilution) (Nacalai Tesque, Kyoto, Japan;
RRID: AB_10013361) was used. Double immunofluorescence for GFP
and NPII or copeptin was performed as described above. Alexa Fluor
546-linked anti-mouse IgG (Molecular Probes, Eugene, OR), Alexa
Fluor 488-linked anti-goat IgG (Molecular Probes), Alexa Fluor
488-linked anti-rat IgG (Molecular Probes), and Alexa Fluor
488-linked anti-rabbit IgG (Molecular Probes) were used for detection
at a dilution of 1:1,000. Images of immunostained sections were cap-
tured by confocal laser scanning microscopy (FluoView 1000, Olym-
pus). The antibodies used in this study are showed in Table 1.
The data are presented as the mean ± SEM and were analyzed
using Statcel4 software. Statistical analyses of the proportion of
copeptin-negative (−) /NPII+ neurons were performed using one-way
TABLE 1 Primary antibodies used in this study
Antigen Description Source, host species, cat# Working dilution RRID
Copeptin Synthetic peptide mapping at the
N-terminal region (7–14) of
mouse copeptin
Generated by our laboratory,
rabbit polyclonal, CP8
1:10,000 (IF)
1:20,000 (IHC)
1:100 (EM)
1:20,000 (WB/DB)
AB_2722604
Copeptin Synthetic peptide mapping at the
C-terminus of mouse copeptin
Santa Cruz Biotechnology, goat
polyclonal, sc-7812 (m-20)
1:15,000 (IF)
1:30,000 (IHC)
1:1,000 (EM)
1:30,000 (WB/DB)
AB_2061966
CRF Human/rat CRF coupled to human
α-globulins via bis-diazotized
benzidine
Donated by Dr. W. Vale, rabbit
polyclonal, PBL rC70
1:20,000 (IF)
1:40,000 (IHC)
1:5,000 (EM)
AB_2314234
GFP His-GFP (full length) fusion protein Nacalai Tesque, rat monoclonal,
04404-84
1:10,000 (IF) AB_10013361
NPI Soluble proteins extracted from the
posterior pituitary of the rat
ATCC, mouse monoclonal, PS60,
CRL-1800
1:1,000 (IF)
1:100 (EM)
AB_2722605
NPII Soluble proteins extracted from the
posterior pituitary of the rat
ATCC, mouse monoclonal, PS41,
CRL-1799
1:1,000 (IF)
1:200 (EM)
1:2,000 (WB)
AB_2313960
AVP AVP conjugated to thyroglobulin Chemicon, rabbit polyclonal,
AB1565
1:2,000 (IF)
1:4,000 (IHC)
AB_90782
Abbreviations: ATCC, American Type Culture Collection; AVP, arginine vasopressin; CRF, corticotropin-releasing factor; DB, dot blotting; EM, immuno-
electron microscopy; GFP, green fluorescent protein; IF, immunofluorescence; IHC, immunohistochemistry; NPI, oxytocin-associated neurophysin I; NPII,
AVP-associated neurophysin II; WB, Western blotting.
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analysis of variance (ANOVA) (in male mice or rats) or two-way
ANOVA (sex difference and right/left difference in mice). When sig-
nificance was found using ANOVA, the post hoc Bonferroni/Dunn
test was performed.
2.4 | Post-embedding immunoelectron microscopy
Preparations were dehydrated through increasing concentrations of
methanol, embedded in LR Gold resin (Electron Microscopy Sciences,
PA), and polymerized under ultraviolet lamps at −20C for 24 hr.
Ultrathin sections (70 nm in thickness) were collected on nickel grids
coated with a Collodion film (or without for triple labeling), rinsed
with PBS several times, then incubated with 2% normal goat serum
and 2% BSA in 50 mM Tris(hydroxymethyl)-aminomethane-buffered
saline (TBS; pH 8.2) for 30 min to block nonspecific binding. The sec-
tions were then incubated with the rabbit polyclonal antiserum against
N-terminal copeptin (CP8, 1:100 dilution), or the goat polyclonal anti-
serum against C-terminal copeptin (m-20, 1:1,000 dilution), and the
PS41 mouse monoclonal antibody against NPII (1:200 dilution) (Castel
et al., 1986) for 2 hr at room temperature. The rabbit polyclonal antise-
rum against rat CRF was also used at 1:5,000 for 2 hr at room temper-
ature. For double immunoelectron microscopy, after incubation with
the primary antibodies, the sections were washed with PBS, then incu-
bated with a goat antibody against rabbit IgG conjugated to 10 nm
gold particles (1:50 dilution) (BBI Solutions, Cardiff, UK) and/or a goat
antibody against mouse IgG conjugated to 15 nm gold particles (1:50
dilution) (BBI Solutions) for 1 hr at room temperature.
Triple immunoelectron microscopy with antibodies for AVP-
associated NPII, oxytocin-associated NPI, and copeptin was per-
formed using the front and back of ultrathin sections mounted on
nickel grids. First, immunocytochemistry with 2 primary antibodies
(anti-NPII; PS41 and copeptin) was performed on one side of the
section and detected using 15 and 10 nm colloidal gold particles.
Next, the other antibody (anti-NPI; PS60) was detected using 5 nm
colloidal gold particles on the other side of the section. Finally, the
sections were contrasted with uranyl acetate and lead citrate and
viewed using an H-7650 (Hitachi, Tokyo, Japan) or JEM-1010 (JEOL,
Tokyo, Japan) electron microscope operated at 80 kV. The antibodies
used in this study are shown in Table 1.
2.5 | Intracerebroventricular injection of a
prohormone convertase inhibitor, hexa-D-arginine
amide
Adult male mice were anesthetized with an intraperitoneal injection
of medetomidine hydrochloride (0.3 mg/kg body weight), midazolam
(4 mg/kg body weight), and butorphanol tartrate (5 mg/kg body
weight) and then placed in the stereotaxic apparatus for the intra-
cerebroventricular injection of the protease inhibitor (furin inhibitor II)
(hexa-D-arginine amide [D6R]) (Sigma, St. Louis, MO) dissolved in PBS.
The needle of a syringe (701 RN) (Hamilton, Reno, NV) filled with
D6R was inserted into the right lateral ventricle (location of the nee-
dle tip: −0.4 mm caudal to the bregma, −1.0 mm lateral to the midline,
2.0 mm below the dura). After inserting the needle, D6R (9 μg in 2 μl
PBS) was infused into the lateral ventricle at a flow rate of 1 μl/min
(n = 6). Control mice were infused with the same volume of PBS
(n = 4). Mice were perfused with fixative 18 hr after D6R or PBS injec-
tion, and then brains were removed. Double immunofluorescence for
NPII and copeptin was then performed as described above.
2.6 | Western blotting
Adult male mice were sacrificed by decapitation to obtain the fresh
brains. Brains were cut into 400 μm thick coronal sections using a vibrat-
ing microtome (7000smz-2; Campden Instruments). For each mouse, a
section containing the SON (Bregma −0.58 to −0.94 mm) region deter-
mined based on the Mouse Brain in Stereotaxic Coordinates (Franklin &
Paxinos, 2007) was mounted on glass, and the SON was dissected bilat-
erally by use of a stainless needle (outer diameter 1.20 mm, inner diame-
ter 0.94 mm). The samples (1/5 SON protein/lane and 1/50 posterior
pituitary protein/lane) were boiled in 10 μl sample buffer containing
62.5 mM trishydroxymethyl-aminomethane-HCl (Tris-HCl; pH 6.8), 2%
SDS, 25% glycerol, 10% 2-mercaptoethanol, and a small amount of
bromophenol blue. Samples were run on a 4–20% SDS-PAGE and elec-
troblotted onto a polyvinylidene difluoride (PVDF) membrane (Bio-Rad
Laboratories, Hercules, CA) using a semidry blotting apparatus (Bio-Rad
Laboratories). Membranes were blocked with PVDF Blocking Reagent
for Can Get Signal (TOYOBO, Tokyo, Japan) for 30 min at room temper-
ature and incubated for 1 hr at room temperature in Can Get Signal Solu-
tion 1 (TOYOBO) with our custom N-terminal copeptin antiserum (CP8,
1:20,000 dilution), with the antiserum raised against the C-terminus of
mouse copeptin (m-20, 1:30,000 dilution), or with the NPII antibody
(PS41, 1:2,000 dilution). Blotted membranes were washed three times
with 0.05% Tween 20 in Tris-HCl-buffered saline (TBST) and incubated
with horseradish peroxidase-conjugated goat polyclonal antibody against
rabbit IgG (Bio-Rad Laboratories) at 1:10,000 dilution, with horseradish
peroxidase-conjugated rabbit polyclonal antibody against goat IgG
(Bio-Rad Laboratories) at 1:10,000 dilution, or with horseradish
peroxidase-conjugated goat polyclonal antibody against mouse IgG (Bio-
Rad Laboratories) at 1:10,000 dilution in Can Get Signal Solution 2
(TOYOBO) for 1 hr at room temperature. After washing for three times
with TBST, blots were visualized by Immun-Star WesternC Chemilumi-
nescence Kit (Bio-Rad Laboratories). Images of the different immuno-
blots were slightly adjusted in brightness and contrast to provide a
uniform background.
Dot blot analysis was further performed with our custom N-terminal
copeptin antiserum (CP8) and the antiserum raised against the C-terminus
of mouse copeptin (m-20). Each antigen of the mouse origin: copeptin7–14
peptide (ATQLDGPA) and copeptin20–39 (RLVQLAGTRESVDSAKPRVY)
were blotted onto the PVDF membrane. The blotted membrane was
immunostained as described above.
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3 | RESULTS
3.1 | Species difference in copeptin expression in
parvocellular neurosecretory neurons in the PVN
Figure 1 shows the amino acid sequences of copeptin in seven mam-
mals including the mouse, rat, and monkey. The epitope against which
the CP8 antiserum was raised is indicated by asterisks above the
sequences. This region is well conserved across mammals (stars below
the sequences) and is identical in the mouse, the rat, the monkey, and
the human. The specificity of our custom N-terminal CP8 copeptin
antiserum was confirmed by an absorption experiment in which the
primary rabbit antiserum against mouse copeptin7–14 was
preabsorbed with an excess amount of mouse copeptin7–14
(ATQLDGPA), whereas the staining was not affected by treatment
with the same concentration of synthetic C-terminus fragment of
mouse copeptin20–39 (RLVQLAGTRESVDSAKPRVY) (Figure 2). Unless
otherwise stated the antiserum is the N-terminal CP8 antiserum. AVP
neurons were immunoidentified with the anti-NPII antibody that has
been well characterized and used as a marker for AVP neurons (Ben-
Barak et al., 1985; Castel & Morris, 1988). Because the localization of
AVP- and NPII-expressing neurons is identical in the rodent brain
(Figures 3 and 4), NPII-immunofluorescence was used as a marker for
AVP neurons in this study.
In the mouse, most magnocellular NPII+ cells also exhibit
copeptin-immunoreactivity in both the PVN and the SON. In the PVN,
however, a major proportion (87%) of NPII+ neurons in the medial
subgroup (PaMP) of parvocellular neurons did not contain
immunodetectable copeptin (Figure 5; arrowheads) (Table 2). These
copeptin−/NPII+ neurons were most prominent in the anterior
parvocellular part (PaAP) (94%) and the posterior parvocellular part
(PaPo) (93%) of the PVN (Figure 5; arrowheads) (Table 2). A prelimi-
nary investigation of various groups of parvocellular neurons (medial,
anterior, and posterior [lateral] groups in mice) revealed no obvious
F IGURE 1 A comparison of the
amino acid sequences of copeptin in
seven mammals including the mouse, the
rat, and the macaque monkey. Residue
identity to mouse copeptin is denoted by
highlight. The antigen epitope site is
highlighted by asterisks above the
sequences (ATQLDGPA). The white
arrow indicates a possible glycosylation
site. The black arrows indicate three
possible cleavage sites. Amino acids
identical to those in other species are
indicated by stars (*). Colon (:) indicates
conserved substitution and period (.)
indicates semiconserved substitution
F IGURE 2 Immunohistochemical analysis of copeptin in the adult
mouse paraventricular (PVN) and supraoptic (SON) nuclei.
Immunoreactivity against copeptin was mainly observed in
magnocellular neurons of the PVN and SON. Controls in which
copeptin antiserum preabsorbed with a saturating concentration of
the antigen (50 μg/ml) for 1 hr at room temperature before use was
substituted for the anti-copeptin antiserum showed a complete
absence of copeptin-like immunoreactivities in the PVN and SON.
Scale bars, 200 μm. OC, optic chiasm; 3V, third ventricle
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differences and was complicated by the lack of an obvious size differ-
ence between magnocellular and parvocellular AVP neurons. No sex
difference or right/left difference was observed in the ratio of
copeptin−/NPII+ neurons in the parvocellular PVN of mice (Table 3).
In contrast to the parvocellular PVN neurons, almost all NPII+ neurons
in the SCN (a nucleus that contains small-sized AVP neurons) did
exhibit copeptin-immunoreactivity (Figure 5). As expected, oxytocin
neurons identified by NPI immunoreactivity did not exhibit copeptin-
immunoreactivity in either the PVN or SON (Figure 6). Similar results
were obtained in the rat (Figure 7), but the proportion of copeptin−/
NPII+ neurons in the parvocellular PVN was less marked (53%) com-
pared with that in the mouse (Table 2). In the macaque monkey,
remarkably, virtually all NPII+ neurons in both the magnocellular and
F IGURE 3 Double-label immunofluorescence for vasopressin
(AVP) and AVP-neurophysin (NPII) in the paraventricular (PVN) and
supraoptic (SON) nuclei, or in the suprachiasmatic nucleus (SCN) in
the mouse. Immunoreactivities against AVP (green) and NPII
(magenta) were merged in each right panel (overlap white),
respectively. The outlined areas in merged images are enlarged at the
bottom right of the figure. Scale bars, 100 μm, and 10 μm in enlarged
images. PaAP, anterior parvocellular part of the PVN; PaMP, medial
parvocellular part of the PVN; PaPo, the posterior part of the PVN
[Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 4 Double-label immunofluorescence for vasopressin
(AVP) and AVP-neurophysin (NPII) in the mouse median eminence
(ME). Immunoreactivities against AVP (green) and NPII (magenta)
were merged in each right panel (overlap white), respectively. The
outlined fibers doubly immunopositive for AVP and NPII. Scale bars,
50 μm, and 5 μm in the enlarged image. 3V, third ventricle [Color
figure can be viewed at wileyonlinelibrary.com]
F IGURE 5 Double-label immunofluorescence for N-terminal
copeptin and vasopressin (AVP)-neurophysin (NPII) in the
paraventricular (PVN) and supraoptic (SON) nuclei, and in the
suprachiasmatic nucleus (SCN) in the mouse. Immunoreactivity
against copeptin (green) and AVP (NPII) (magenta) was merged in each
right panel (overlap white), respectively. The outlined areas in merged
images are enlarged at the bottom right of the figure. Arrowheads
indicate AVP (NPII)-immunoreactive parvocellular PVN neurons that
did not express immunodetectable amounts of copeptin. Scale bars,
100 μm, and 10 μm in enlarged images. PaAP, anterior parvocellular
part of the PVN; PaMP, medial parvocellular part of the PVN; PaPo,
the posterior part of the PVN [Color figure can be viewed at
wileyonlinelibrary.com]
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parvocellular division were also copeptin-immunoreactive (Figure 8).
No obvious sex difference was observed in monkeys in terms of
copeptin- and NPII-immunoreactivity.
In the internal layer of the ME that contains axons of mag-
nocellular neurons originating from the PVN or SON and projecting
to the posterior pituitary, virtually all NPII+ fibers exhibited
copeptin-immunoreactivity in the mouse, rat, and monkey (Figure 9a).
However, in the external layer of the mouse ME, where the
parvocellular CRF axons terminate, copeptin immunoreactivity
could be detected in only a small number of NPII+ fibers (Figure 9a;
arrowheads). In the external layer of the rat ME, co-expression of
NPII- and copeptin-immunoreactivity was observed more frequently
in the external layer of the ME than in the mouse, but less fre-
quently than in the monkey (Figure 9b; arrowheads). In the macaque
monkey, most NPII+ fibers were copeptin-immunoreactive in both
the internal and external layer of the ME (Figure 9c; arrowheads).
3.2 | Expression of NPII or copeptin in
parvocellular CRF neurons in mice
Expression of NPII and CP8-detectable copeptin in the parvocellular
CRF neurons was examined in the CRF-VenusΔNeo mouse. In the
parvocellular PVN, very few (one or two cells per section) Venus+ neu-
rons showed NPII-immunoreactivity (Figure 10a; arrowheads) or
copeptin-immunoreactivity (Figure 10b; arrowheads). We next studied
co-localization of CRF with NPII in the ME of a wild-type mouse.
CRF-immunoreactive fibers were detectable only in the external layer
of the ME, and approximately half of the CRF-immunoreactive fibers
contained NPII-immunoreactivity (Figure 10c; arrowheads). NPII+
fibers were intensively stained in the internal layer of the mouse ME
of the wild-type mouse, but were devoid of CRF-immunoreactivity
(Figure 10c). However, NPI+ fibers were hardly observed in the exter-
nal layer of the ME in the mouse (Figure 11).
Preliminary experiments using a copeptin m-20 antiserum raised
against an epitope near the C-terminus of mouse copeptin20–39 rev-
ealed copeptin-immunoreactivity in virtually all NPII-expressing mag-
nocellular and parvocellular neurons in the mouse PVN (Figure 12).
The specificity of the Santa Cruz copeptin antiserum (m-20) was con-
firmed by an absorption experiment in which the primary goat antise-
rum against the C-terminus of mouse copeptin was preabsorbed with
an excess amount of synthetic C-terminus fragment of mouse
copeptin20–39 (RLVQLAGTRESVDSAKPRVY), whereas the staining
was not affected by treatment with the same concentration of mouse
N-terminus fragment of mouse copeptin7–14 (ATQLDGPA) (Figure 2).
TABLE 2 Proportion (%) of
N-terminal-copeptin-negative/
vasopressin-associated NP II-positive
neurons in the mouse and rat
parvocellular PVN of the hypothalamus
in males
Number of males PaAP PaMP PaV PaPo Total
Mouse 5 94.0 ± 0.5* 87.3 ± 1.1 84.8 ± 0.3 93.2 ± 0.3* 89.6 ± 0.3
(n = 4,461)
Rat 4 60.2 ± 2.7 62.5 ± 4.1 55.1 ± 5.1 20.5 ± 4.5† 53.1 ± 1.7
(n = 2,941)
Abbreviations: NP, neurophysin; PaAP, anterior parvocellular part of the PVN; PaMP, medial parvocellular
part of the PVN; PaV, the ventral part of the PVN; PaPo, the posterior part of the PVN; PVN, para-
ventricular nucleus.
*p < .01, versus PaMP and PaV.
†p < .01, versus PaAP, PaMP, and PaV.
TABLE 3 Proportion (%) of
N-terminal-copeptin-negative/
vasopressin-associated NP II-positive
neurons in the parvocellular of the
hypothalamus in mice
Number of animals Left Right Total
Male 5 89.1 ± 0.5 90.1 ± 0.9 89.6 ± 0.3 (n = 4,461)
Female 4 89.1 ± 0.4 89.0 ± 0.2 89.1 ± 0.2 (n = 3,580)
Abbreviations: NP, neurophysin; PVN, paraventricular nucleus.
F IGURE 6 Double-label immunofluorescence for copeptin and
oxytocin-neurophysin (NPI) in the mouse paraventricular (PVN)
(middle part) and supraoptic (SON) nuclei. Immunoreactivities against
copeptin (green) and NPI (magenta) were merged in each right panel,
respectively. Scale bars, 100 μm. OC, optic chiasma; 3V, third ventricle
[Color figure can be viewed at wileyonlinelibrary.com]
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3.3 | Co-localization of copeptin with NPII within
secretory vesicles in mice
Triple immunoelectron microscopy was carried out to examine co-
localization of NPII, NPI, and CP8-detectable copeptin within neuro-
secretory vesicles in the mouse. Both NPII and copeptin were
detected within axons of neurosecretory neurons in the posterior
pituitary, where they were co-associated within neurosecretory vesi-
cles (Figure 13a,b). NPI was also detected in axon terminals, but no
copeptin-immunoreactivity was observed in NPI-labeled terminals
adjacent to NPII-labeled terminals (Figure 13c). Numerous neurose-
cretory vesicles located in cell bodies and dendrites of magnocellular
neurons in the SON were immunolabeled for both copeptin and NPII
(Figure 14a–c). However, copeptin-immunoreactivity was not
observed in immature neurosecretory vesicle cores within the Golgi
apparatus (Figure 15). In magnocellular neurons in the PVN, many
neurosecretory vesicles were labeled for both copeptin and NPII and
the vesicles were 160 nm in diameter (Figure 16a). The size was sim-
ilar to that of neurosecretory vesicles in the SON (Figures 14–16). In
parvocellular PVN neurons, there were also numerous dense-cored
neurosecretory vesicles (100 nm in diameter) that contained NPII-
immunoreactivity, but these vesicles were devoid of copeptin-
immunoreactivity (Figure 16b; arrows).
Next, we examined co-localization of NPII and copeptin in the
mouse ME. The two layers of the ME, that is, the internal and external
layers, investigated in the present immunoelectron microscopy, are
shown schematically in Figure 17a. In the internal layer of the ME,
immunoreactivity for both NPII and copeptin was intense in
F IGURE 7 Double-label immunofluorescence for N-terminal
copeptin and vasopressin (AVP)-neurophysin (NPII) in the
paraventricular (PVN) and supraoptic (SON) nuclei, and in the
suprachiasmatic nucleus (SCN) in the rat. Immunoreactivity against
copeptin (green) and AVP (NPII) (magenta) was merged in each right
panel (overlap white), respectively. The outlined areas in merged
images are enlarged at the bottom right of the figure. Arrowheads
indicate AVP (NPII)-immunoreactive parvocellular PVN neurons that
did not (or very weakly) express immunodetectable amounts of
copeptin. Scale bars, 100 μm, and 10 μm in enlarged images. PaAP,
anterior parvocellular part of the PVN; PaMP, medial parvocellular
part of the PVN; PaPo, the posterior part of the PVN [Color figure can
be viewed at wileyonlinelibrary.com]
F IGURE 8 Double-label immunofluorescence for N-terminal
copeptin and vasopressin (AVP)-neurophysin (NPII) in the
paraventricular (PVN) and supraoptic (SON) nuclei, and in the
suprachiasmatic nucleus (SCN) in the macaque monkey.
Immunoreactivity against copeptin (green) and AVP (NPII) (magenta)
was merged in each right panel (overlap white), respectively. The
outlined areas in merged images are enlarged at the bottom right of
the figure. Virtually all NPII+ neurons in both the magnocellular and
parvocellular division were also copeptin-immunoreactive
(arrowheads). Scale bars, 100 μm, and 10 μm in enlarged images. PaAP,
anterior parvocellular part of the PVN; PaMP, medial parvocellular
part of the PVN [Color figure can be viewed at
wileyonlinelibrary.com]
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neurosecretory axons, and co-associated within the neurosecretory
vesicles (Figure 17b). The size of these vesicles was 160 nm in diam-
eter, characteristic of those of magnocellular neurons in rodents
(Armstrong & Tian, 1991; Pow & Morris, 1989; Satoh et al., 2015).
However, in the external layer of the mouse ME, although many NPII+
dense-cored vesicles (100 nm in diameter) were present in axon ter-
minals, as reported previously (Shaw, Castel, & Morris, 1987), in most
terminals the CP8 antiserum detected little or no copeptin immunore-
activity associated with the vesicles (Figure 17c; white arrows). Many
neighboring axons contained dense-cored vesicles that were immuno-
reactive for neither NPII nor copeptin (Figure 17c; black arrows). In a
small proportion of nerve terminals in the external layer of the mouse
ME, however, dense-cored vesicles containing both CRF- and NPII-
immunoreactivity (Figure 17d; white arrows) were present, as
expected.
3.4 | Effects of intracerebroventricular injection
of a prohormone convertase inhibitor, D6R on the
immunoreactivity for copeptin and NPII in mice
We hypothesized that processing of AVP precursor may differ
between neuronal populations. Therefore, D6R was injected
intracerebroventricularly to inhibit the activity of PC1/3, which is a
key processing enzyme required for the cleavage of the AVP precur-
sor in the mouse (Figure 18). In the D6R-injected group, many NPII+
magnocellular neurons (magenta) exhibited only a faint
F IGURE 9 Double-label immunofluorescence for N-terminal
copeptin and vasopressin (AVP)-neurophysin (NPII) in the median
eminence (ME). Representative results are displayed in the mouse (a),
in the rat (b), and in the macaque monkey (c). Immunoreactivity
against copeptin (green) and AVP (NPII) (magenta) was merged in each
right panel (overlap white), respectively. The outlined areas in merged
images are enlarged at the top right of the figure. Arrowheads indicate
fibers doubly immunopositive for copeptin and AVP (NPII). Scale bars,
50 μm, and 5 μm in enlarged images. 3V, third ventricle [Color figure
can be viewed at wileyonlinelibrary.com]
F IGURE 10 Double-label for corticotropin-releasing factor (CRF)
and vasopressin (AVP)-neurophysin (NPII) (a) or copeptin (b) in the
medial parvocellular part of the paraventricular nucleus (PaMP) of the
CRF-VenusΔNeo mouse. Each outlined area in the merge image is
enlarged at the bottom right of the figure. Arrowheads indicate cells
doubly immunopositive for CRF-Venus and AVP (NPII) in (a) or single
positive for CRF-Venus in (b). (c) In the median eminence (ME) of the
wild-type mouse, CRF-immunoreactive fibers were exclusively
observed in the external layer, and approximately half of CRF-
immunoreactive fibers contained immunodetectable amounts of AVP
(NPII) (arrowheads). Many AVP (NPII)-immunoreactive fibers were
seen in the internal layer. Scale bars, 50 μm, and 10 μm in enlarged
images. IF, immunofluorescence [Color figure can be viewed at
wileyonlinelibrary.com]
F IGURE 11 Double-label immunofluorescence for copeptin and
oxytocin-neurophysin (NPI) in the mouse median eminence (ME).
Immunoreactivities against copeptin (green) and NPI (magenta) were
merged in the right panel. Scale bar, 50 μm. OC, optic chiasma; 3V,
third ventricle [Color figure can be viewed at wileyonlinelibrary.com]
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immunoreactivity for copeptin (green) in either the PVN or the
SON (Figure 18; arrowheads), whereas in the PBS-injected con-
trols most magnocellular NPII+ cells exhibited strong copeptin-
immunoreactivity (Figure 18). Unexpectedly, several magnocellular
neurons that contained copeptin-immunoreactivity but little or no
NPII-immunoreactivity were present in the PVN and the SON in the
D6R-treated group (Figure 18; arrows in magno-PVN and SON). The
effect of D6R was also evident in the SCN; NPII+ neurons were
copeptin-immunoreactive (copeptin+/NPII+) in the control group
(Figure 18), but were almost devoid of copeptin-immunoreactivity in
the D6R-treated animals (Figure 18; arrowheads in SCN) (shown in
magenta). In the parvocellular PVN, NPII+ neurons were mostly
copeptin−/NPII+ (Figure 18; arrowheads in parvo-PVN), and neither the
number of NPII-immunoreactive neurons nor the copeptin-immunore-
activity in NPII+ neurons was affected significantly by D6R treatment
(Figure 18; arrowheads in parvo-PVN). In the ME, D6R administration
had no very obvious effect on the immunostaining for either copeptin
or NPII, although NPII-immunoreactivity appeared to decrease a little
in the D6R-treated group (Figure 18). Finally, we examined the effect
of D6R treatment on AVP peptide immunoreactivity by use of an AVP
peptide antiserum. No effect of D6R injection on AVP (mature neuro-
peptide) staining was observed (Figure 19).
F IGURE 12 Double-label immunofluorescence for copeptin
(by using a goat polyclonal antibody against to near the C-terminus of
copeptin of mouse origin) and vasopressin-neurophysin (NPII) in the
mouse paraventricular nucleus (PVN) (middle part).
Immunoreactivities against copeptin (green) and NPII (magenta) were
merged in each right panel, respectively. Scale bar, 100 μm [Color
figure can be viewed at wileyonlinelibrary.com]
F IGURE 13 Triple immunoelectron microscopy for vasopressin
(AVP)-neurophysin (NPII), oxytocin (OXT)-neurophysin (NPI), and
N-terminal copeptin in the mouse posterior pituitary. (a) AVP (NPII)
(signaled by 15-nm gold particles) and copeptin (signaled by 10-nm
gold particles) were both detected within the terminals of
magnocellular neurosecretory axons. (b) Enlarged image shows that
the immunoreactivity was co-associated with the neurosecretory
vesicle structures in the same terminal. (c) In contrast, no copeptin-
immunoreactivity was detected in neighboring OXT (NPI)-labeled
(by 5-nm gold particles) terminals. Scale bars, 500 nm in (a), and
200 nm in enlarged images (b and c). m, mitochondrion
F IGURE 14 Double immunoelectron microscopy for N-terminal
copeptin and vasopressin (AVP)-neurophysin (NPII) in the supraoptic
nuclei (SON) of the mouse. Numerous neurosecretory vesicles
(arrows) located in the dendrites (Den) in (a) and cell bodies of SON
neurons in (b) were doubly immunopositive for copeptin (signaled by
10-nm gold particles) and NPII (signaled by 15-nm gold particles). The
outlined area in (b) is enlarged in (c). Scale bars, 200 nm in (a), 500 nm
in (b), 50 nm in (c). Gol, Golgi apparatus; m, mitochondrion;
Nuc, nucleus
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3.5 | Copeptin antisera recognize the processed
peptide, but apparently cannot recognize copeptin
when it is still part of the prohormone
Finally, we conducted Western blot analysis of the extracts from
mouse SON (magnocellular cell body region) and posterior pituitary
(terminal region where the precursor processing is complete). The
anti-NPII antiserum (PS41), anti-copeptin7–14 antiserum (CP8), and
Santa Cruz antiserum raised against the C-terminus of mouse
copeptin (m-20) were used to examine whether the mature NPII
molecule and/or an NPII/copeptin fusion protein molucule could be
detected in the respective tissue. We also performed an immuno-
blotting study for detecting the N-terminus peptide of copeptin with
the CP8 antiserum, and for the C-terminus peptide with the m-20
antiserum. A single NPII+ band at 11 kDa was observed in the
mouse SON and pituitary (Figure 20). Because the molecular mass of
whole copeptin is 4 kDa, 15 kDa is the expected total molecular
mass of the copeptin and NPII fusion protein. However, a band
corresponding to 15 kDa could not be detected either the CP8
(recognizing copeptin7–14) or m-20 (recognizing the C-terminus of
copeptin) in the extracts from the SON or the pituitary (Figure 20).
In addition, our dot blot analysis showed that either of the copeptin
antisera (CP8 and m-20) specifically recognize each antigen peptide
(Figure 21).
F IGURE 15 Immunoelectron microscopy for copeptin (with the
antiserum raised against to near the C-terminus of copeptin of mouse
origin: m-20, 10 nm gold particles) in the supraoptic nucleus (SON) of
the mouse. Neurosecretory vesicles (arrows) located in the cell bodies
of SON neurons were immunopositive for copeptin (signaled by
10-nm gold particles) (white arrows). Copeptin-immunoreactivity was
not observed in immature neurosecretory vesicles in the Golgi
apparatus (black arrows). Scale bar, 500 nm. Gol, Golgi apparatus;
m, mitochondrion
F IGURE 16 Double immunoelectron microscopy for N-terminal
copeptin and vasopressin (AVP)-neurophysin (NPII) in the
paraventricular nucleus (PVN) of the mouse. (a) In the cell bodies of
the magnocellular PVN neurons, numerous neurosecretory vesicles
(arrows) were also doubly immunoreactive for copeptin (signaled by
10-nm gold particles) and AVP (NPII) (signaled by 15-nm gold
particles). (b) In contrast, although many NPII-immunoreactive dense-
cored vesicles (signaled by 10-nm gold particles; arrows) were
observed in the cell bodies of the parvocellular PVN neurons, they
contained essentially no copeptin-immunoreactivity. Scale bars,
200 nm. Gol, Golgi apparatus; m, mitochondrion
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4 | DISCUSSION
Across all three species examined in the present study, most NPII+
cells exhibited strong copeptin-immunoreactivity in either the SON,
which contains only magnocellular neurons, or the magnocellular part
of the PVN. Light-microscopic immunoreactivity for NPII and copeptin
was observed throughout the intracellular compartment of mag-
nocellular neurons including perikarya, dendrites, and axons. In the
mouse, immunoelectron microscopy demonstrated that copeptin-
immunoreactivity always co-localized with NPII-immunoreactivity in
neurosecretory vesicles in the posterior pituitary that contains nerve
endings of magnocellular neurons originating from the PVN and the
SON. In contrast to an unequivocal co-localization of NPII and
copeptin in magnocellular neurons, a great majority (90%) of puta-
tive parvocellular neurons that are NPII-immunoreactive was devoid
of copeptin-immunoreactivity in the mouse PVN, although the bound-
ary between the magnocellular part and the parvocellular part was not
always clear, and parvocellular neurons could not easily be distin-
guished from magnocellular neurons by Nissl staining (Biag
et al., 2012). In particular, parvocellular neurons were mostly
F IGURE 17 Double immunoelectron microscopy for vasopressin
(AVP)-neurophysin (NPII) and N-terminal copeptin or corticotropin-
releasing factor (CRF) in the mouse median eminence (ME).
(a) Schematic drawing of the ME showing the area observed by the
electron microscopy. (b) In the internal layer of the ME (area of the
magnocellular axons), AVP (NPII) and copeptin were both detected
within the terminals of neurosecretory axons, and co-associated with
the neurosecretory vesicle structures in the same terminal. Electron
photomicrographs illustrating the presence of AVP (NPII)-
immunoreactive (signaled by 15-nm gold particles) and copeptin (c) or
CRF-immunoreactive (signaled by 10-nm gold particles) (d) on dense-
cored vesicles of nerve endings co-localized in the external layer of
the ME. Some vesicles were clearly AVP (NPII)-positive (white arrows),
but copeptin could not be detected; vesicles in other terminals were
negative for both (black arrows) (c). In contrast, many vesicles which
were immunopositive for AVP (NPII) were also positive for CRF (white
arrows) (d). Scale bars, 200 nm. 3V, third ventricle; m, mitochondrion
F IGURE 18 Double-label immunofluorescence for N-terminal
copeptin and vasopressin (AVP)-neurophysin (NPII) in the
magnocellular part of the paraventricular nucleus (magno-PVN), the
supraoptic nucleus (SON), the suprachiasmatic nucleus (SCN), the
parvocellular part of the PVN (parvo-PVN), and the median eminence
(ME) in the mouse. Representative results are displayed for control
tissues (left; control) and identical areas after the
intracerebroventricular administration of a prohormone convertase
inhibitor (hexa-D-arginine amide; D6R) (right; D6R-treated).
Immunoreactivity against copeptin (green) and AVP (NPII) (magenta)
was merged in each panel (overlap white). Arrowheads indicate
neurons single immunodetectable for AVP (NPII). Arrows indicate
neurons in which only copeptin was immunodetectable. Scale bar,
50 μm [Color figure can be viewed at wileyonlinelibrary.com]
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copeptin−/NPII+ in the PaAP (94%) and the posterior parvocellular
lateral part (PaPo) (93%) of the PVN in the mouse. In the rat,
copeptin-immunoreactivity could not be identified in approximately
half (53%) of the NPII-immunoreactive neurons in the parvocellular
part of the PVN.
The reason(s) for the disproportionately low levels of CP8-
immunodetectable copeptin compared with those of NPII and AVP in
a substantial proportion of NPII+ parvocellular neurons of rats and
mice is not clear at present. Proteolytic processing occurs at the diba-
sic residue lysine-arginine (KR) between the AVP moiety and NPII
moiety of the pro-AVP molecule or at the monobasic R site between
the NPII moiety and copeptin moiety of the prohormone. Cathepsin L
cleaves preferentially the amino terminal of the KR residue, whereas
the prohormone convertase family of subtilisin-like proteases
(e.g., PC1/3, PC2, PC5) are involved in the cleavage of carboxyl termi-
nals of the KR residue (Hook et al., 2008). Cleavage of the monobasic
R site may be catalyzed by a different processing enzyme(s), so pro-
AVP processing may take place as a two-step reaction, although a
specific enzyme for the monobasic R site cleavage has not yet been
F IGURE 19 Double-label immunofluorescence for vasopressin
(AVP) and AVP-neurophysin (NPII) in the magnocellular part of the
paraventricular nucleus (magno-PVN), the supraoptic nucleus (SON),
the suprachiasmatic nucleus (SCN), the parvocellular part of the PVN
(parvo-PVN), and the median eminence (ME) in the mouse.
Representative results are displayed for control tissues (left; control)
and identical areas after the intracerebroventricular administration of
a prohormone convertase inhibitor (hexa-D-arginine amide; D6R)
(right; D6R-treated). Immunoreactivity against AVP (green) and AVP
(NPII) (magenta) was merged in each panel (overlap white). Scale bar,
50 μm [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 20 Western blot analysis with our custom copeptin7–14
(CP8) antiserum, the C-terminus directed Santa Cruz copeptin
antiserum (m-20), and a vasopressin (AVP)-neurophysin (NPII) (PS41)
monoclonal antibody on similar blots of supraoptic nucleus (SON) and
posterior pituitary. A single NPII+ band at 11 kDa was observed in
the mouse SON and posterior pituitary. No band could be detected
by either of the copeptin antisera at a molecular weight
corresponding to a putative NPII/copeptin fusion protein (15 kDa)
in the extracts of either the mouse hypothalamus or pituitary
F IGURE 21 Dot blot analysis of antigen peptides probed with
our custom copeptin antiserum (CP8) and the antiserum raised against
the C-terminus of mouse copeptin (m-20). Each antigen of the mouse
origin: copeptin7–14 peptide (ATQLDGPA) and copeptin20–39
(RLVQLAGTRESVDSAKPRVY) were blotted onto the polyvinylidene
difluoride membrane (10−4 M, 10−5 M, 10−6 M, 10−7 M, 10−8 M, and
0 M). Both antibodies recognized each antigen peptide specifically up
to 10−6 M
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identified. Therefore, one possible explanation for our finding is that
the second cleavage between NPII and copeptin does not take place
adequately in parvocellular AVP-expressing neurons in rats and mice,
possibly through a paucity of a monobasic R protease, and despite the
presence of the K/R protease. Indeed, no effect of D6R injection on
AVP staining was found in this study, suggesting that a D6R-sensitive
enzyme is not involved in the first step of processing (AVP-cleavage
and circularization) in mouse AVP neurons. It has been reported that
D6R inhibits PC1/3, but does not affect the activity of PC2 (Cameron,
Appel, Houghten, & Lindberg, 2000). As yet, for mice, nothing is
known of the concentration of the convertases or whether enzymatic
activities, such as PC1 and PC2 in parvocellular PVN neurons differ
from those of magnocellular AVP neurons. However, for rats, Dong
et al. (1997) and Schafer et al. (1993) have both reported that, in the
parvocellular PVN neurons, PC2 expression was greater but PC1
expression was much lower than that in the magnocellular PVN and
SON neurons. These results suggest that the differential distribution
of prohormone convertases between magnocellular and parvocellular
PVN subdivisions could play a role in the processing of AVP
prohormone in the different cell types. It is possible that, in the rat
and mouse, copeptin had been cleaved enzymatically into smaller
fragments that were undetectable by our N-terminal custom copeptin
antiserum (CP8). Mass spectrometry analysis might, in theory, be able
to demonstrate the fragmentation of copeptin in the parvocellular cell
bodies. However, the low region-specific resolution of quantitative
mass spectrometry at present precludes demonstration of the frag-
mentation of copeptin in only a subpopulation of parvocellular PVN
neurons. Furthermore, our preliminary observation that copeptin
could be detected in PVN parvocellular neurons by the m-20 antise-
rum, which was raised against an epitope close to the C-terminus of
mouse copeptin (see Figure 12), shows that the C-terminus at least is
intact and available to the antiserum. Our Western blotting experi-
ment using the two copeptin antisera (CP8 and m-20) showed that
neither antiserum detected a positive band at a molecular weight
(15 kDa) corresponding to copeptin incorporated as part of the AVP
precursor in extracts of either mouse hypothalamus or pituitary. Our
dot blot analysis also supports our hypothesis that both copeptin
antisera specifically recognize each antigen peptide (Figure 21). In
addition, we previously reported by Western blot analysis that our
custom copeptin7–14 antiserum (CP8) specifically recognizes the
copeptin1–14 (fragment)-GFP fusion protein (Satoh et al., 2015). Fur-
thermore, our post-embedding immunoelectron microscopy showed
that immunoreactivity to our custom copeptin7–14 antiserum (CP8),
the Santa Cruz copeptin polyclonal antiserum (m-20), and the anti-
NPII monoclonal antibody (PS41) could all be detected in neurosecre-
tory vesicles within magnocellular AVP neurons, but apparently not in
immature vesicle cores within the Golgi apparatus. Taken together,
these results indicate that both copeptin antisera used in this study
recognize only the processed peptide, and do not recognize copeptin
when it is still part of a prohormone. In sharp contrast to the lack of
copeptin-immunoreactivity in most NPII+ parvocellular neurons in the
rodent PVN, most parvocellular PVN NPII+ neurons in the monkey
exhibited prominent copeptin-immunoreactivity, demonstrating a
striking species difference in copeptin expression between rodents
and the monkey in NPII-immunoreactive CRF parvocellular neurons in
the PVN. Taken together, these results suggest that there is a differ-
ence between magnocellular and parvocellular neurons in the proteo-
lytic processing of the AVP precursor in rodents, but it remains
unclear whether this is simply a difference in the speed of processing,
and what might be its functional import.
Glycosylation of copeptin increases the stability of the peptide
and its plasma half-life (Bhandari et al., 2009; Blanchard et al., 2013;
Bolignano et al., 2014; Wuttke et al., 2013). Therefore, a third possible
explanation for the relative lack of CP8-detectable copeptin in rodent
parvocellular neurons would be that the glycosylation has not been
completed in these neurons, leading to rapid breakdown of copeptin.
Our preliminary finding that the copeptin is, however, detectable with
the m-20 C-terminal antiserum makes this possibility unlikely.
It has long been known that a subset of CRF neurons in the PVN
co-expresses AVP in rats (Whitnall et al., 1985), mice (Whitnall, 1993),
and humans (Mouri et al., 1993; Whitnall, 1993). CRF and AVP are co-
secreted from nerve endings in the ME into capillaries, and reach the
anterior pituitary via portal vessels to stimulate synergistically the
release of ACTH from corticotrophs (Jones & Gillham, 1988). It is cur-
rently unclear whether only a subset of CRF neurons is capable of
expressing AVP, or whether the transcription of the AVP gene and/or
the subsequent production of AVP peptide are dependent on neural
and humoral factors influencing the activity of the cell. Although very
few parvocellular neurons are immunopositive for both CRF and AVP
in unstressed mice, exposure to stress (Whitnall, 1993) or adrenalec-
tomy (Itoi et al., 2014) increases dramatically the number of doubly
immunopositive cells. In the external layer of the ME, about half of
the parvocellular CRF nerve endings contain detectable AVP in the rat
(Whitnall, 1993; Whitnall et al., 1985), whereas in the mouse virtually
all CRF neurosecretory axons in the external layer of the ME contain
AVP (Whitnall, 1993). In humans, AVP can be detected in all CRF neu-
rons, depending on the premortem conditions (Mouri et al., 1993).
In the present study, very few CRF+ neurons in the PVN of the
CRF-VenusΔNeo mouse exhibited N-terminal copeptin-immunoreac-
tivity, at least under normal unstressed circadian glucocorticoid levels,
a finding consistent with an idea that AVP expression in CRF neurons
is sensitive to stress and circulating glucocorticoid concentrations (Itoi
et al., 2014). Another subpopulation of CRF+ and/or AVP+
parvocellular PVN neurons is known to project to autonomic centers
in the brainstem and spinal cord, and it is likely that these neurons are
unresponsive to negative feedback by glucocorticoids
(Sawchenko, 1987). The copeptin status of this subpopulation of neu-
rons remains to be determined.
In the mouse, very little copeptin-immunoreactivity could be
identified in nerve terminals of parvocellular CRF neurons at the
external layer of the ME with the N-terminal CP8 antiserum, and
the reason for this remains unclear. It is reported that, in the ox,
copeptin (39aa: 1–39) is metabolized into several small peptides of
10aa (1–10), 18aa (1–18), 17aa (23–39), and 14aa (26–39) residues
(Land et al., 1982; Smyth & Massey, 1979). If copeptin in the mouse
parvocellular neurons is metabolized rapidly, then this could explain
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why it was undetectable in most, but not all, nerve fibers in the exter-
nal ME with the CP8 antiserum. In particular, peptides produced by
enzymatic cleavage between 10[L] and 11[D] may not be identified
because our custom CP8 copeptin antiserum was raised against an
epitope that encompasses amino acid residues 7[A] to 14[A]. However,
copeptin-immunoreactivity was readily detectable with the CP8 anti-
serum in some NPII-expressing nerve endings at the external layer of
the ME in the rat and the monkey, reiterating the species difference
in copeptin-immunoreactivity. Furthermore, our preliminary study
shows that the m-20 C-terminal antiserum can detect copeptin immu-
noreactivity in both the cell bodies and the terminals of parvocellular
NPII+ neurons of mice (Figure 12), which indicates that the C-terminal
epitope has not been metabolized to the extent that it is unre-
cognizable. Interpretation of any apparent differences in immunocyto-
chemical detection of parvocellular neuropeptides between the cell
bodies and terminals is difficult because of the concentration of the
neurosecretory vesicles in the axon terminals (Morris, 2020). How-
ever, relatively slow processing of the pro-AVP precursor could
explain why copeptin-immunoreactivity in the ME was more intense
than that in the parvocellular PVN perikarya. Although AVP neurons
in the SCN are also small-sized neurons, virtually all NPII+ SCN neu-
rons were copeptin+/NPII+ in both mice and rats. Thus, SCN neurons
resemble magnocellular neurons in terms of the N-terminal (CP8)
copeptin-immunoreactivity.
Intracerebroventricular administration of a prohormone con-
vertase inhibitor, D6R, resulted in a marked reduction of copeptin-
immunoreactivity in the NPII-immunoreactive magnocellular PVN
neurons and in SCN neurons in the mice. This result raises the possi-
bility that insufficient processing of the prohormone could explain
the lack of N-terminal copeptin immunoreactivity in a subpopulation
of NPII (AVP)-expressing parvocellular neurons. Indeed, the second
cleavage (between NPII and copeptin residues) is incomplete in birds
and amphibians, and a two-domain protein comprising NPII and
copeptin has been identified as a “big NP” in the posterior pituitary
and in the circulation (Acher, 1980; Michel, Chauvet, Chauvet, &
Acher, 1987). The absence of S S bonds in the “big NP” is likely to
have resulted in an alteration in three-dimensional structure and
could provide another explanation for the lower NPII (PS41) immu-
nostaining of magnocellular neurosecretory neurons in the D6R-
treated animals. As mentioned above, our Western blot evidence
(Figure 20) indicates that neither the N-terminal (CP8) nor the
C-terminal (m-20) copeptin antisera used in this study recognize any
precursor protein like ”big NP” in extracts of the SON or posterior
pituitary. In addition, D6R is known to be predominantly a furin
inhibitor (Cameron et al., 2000), and both Schafer et al. (1993) and
Dong et al. (1997) reported the ubiquitous presence of furin in the
PVN and SON.
Copeptin has long been regarded as biologically inactive
(Morgenthaler et al., 2008). However, recent advances in research
on the glycopeptide mean that it is now widely accepted that
copeptin possesses multi-faceted biological properties. For example,
copeptin is required for correct folding of the AVP precursor, and its
absence may lead to an inefficient monomer folding that contributes
to the pathogenesis of human hypothalamic diabetes insipidus (Barat,
Simpson, & Breslow, 2004). Roles of copeptin in modulating cellular
functions have also been explored, and it has been reported that
copeptin causes a low amplitude, slow increase of [Ca2+]i in a popula-
tion of cultured rat hypothalamic neurons (Gao et al., 2008). Copeptin
(both copeptin 1–39 [full length] and the C-terminal fragment 22–39)
also potentiate the amplitude of excitatory postsynaptic potentials
evoked in neurons of the rat lateral septum (van den Hooff, Seger,
Burbach, & Urban, 1990), indicating that the C-terminal component of
copeptin may modulate neuronal activity in the brain.
In conclusion, N-terminal copeptin-immunoreactivity was not
detectable (or was present in disproportionately low concentrations)
in a subpopulation of AVP-expressing parvocellular neurons in the
PVN of rodents, but was present in virtually all AVP-expressing mag-
nocellular neurons in the PVN and SON. This difference between
parvocellular and magnocellular copeptin expression was not
observed in the monkey, and was not seen when the copeptin was
detected with a C-terminal copeptin antiserum. This study has rev-
ealed not only that there are species differences in the processing of
the pro-AVP precursor and production of free copeptin, but also that
the processing may not be the same in different groups of pro-AVP-
expressing cells within a given species. At the moment, there is an
increasing use of plasma copeptin measurements as a surrogate
marker for AVP measurements in human clinical problems such as dia-
betes insipidus, sepsis and cardiovascular disease (Morgenthaler
et al., 2008). Future research on macaques could provide valuable and
relevant information on copeptin processing and plasma copeptin
levels under conditions such as dehydration and other stresses. How-
ever, relatively little is currently known about the control of pro-AVP
precursor processing in humans, the enzymes involved, and the extent
to which the various antibodies used to detect copeptin recognize the
possible different molecular weight forms. Our results, which reveal
for the first time differences among rodents and macaques, strongly
suggest that this is an area which deserves further experimental
exploration.
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